GLP1
-
Rapid weight loss can cause a greater loss of muscle mass than losing weight slowly. The popularity of newer weight-loss drugs that shed pounds quickly has raised concerns among researchers about how this will affect the health of our muscles.
-
The race is on to deliver the first once-a-day weight-loss pill that would be both cheaper and less invasive than the current injectable drugs, with strong results from Terns following those from competitors Eli Lilly, Pfizer, Roche and Structure.
-
People living with diabetes might have a new hope. Scientists have tested a new drug therapy in diabetic mice, and found that it boosted insulin-producing cells by 700% over three months, effectively reversing their disease.
-
Next-gen anti-obesity drugs like injectable liraglutide, sold as Saxenda, deliver impressive results in the first 12 months. New research looks into what happens to those results once treatment stops.
-
In yet another surprise attribute of the new class of obesity drugs, scientists have found that GLP-1 receptor agonists can also subdue brain inflammation, giving them a potential ‘superpower’ in the fight against Alzheimer’s and Parkinson’s diseases.
-
Scientists have found that linking two hormones into a single molecule has the potential for improving the treatment of metabolic disorders such as type 2 diabetes and obesity.